Clinical Trial Update: Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

View source ↗

Summary

Real-world study of first-line palbociclib combinations in HR+/HER2- advanced/metastatic breast cancer in Latin America; completed with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer Metastatic

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: Pfizer | Conditions: Breast Cancer Metastatic | Status: COMPLETED | Results posted: 2024-01-26